Intellipharmaceutics International Inc. (IPCI)

[fabius]

I cannot find one single reason to decide not to inform the market about new trials (of whatever study) being conducted.

So it is difficult to me thinking about IPCI really having conducted or conducting any trials without putting out a PR; my understanding is that these are undoubtely MATERIAL INFORMATION and accordingly should be realeased to the the public in order to avoid insder trading and market manipulation. Material info HAS TO BE publicly disseminated in order to preserve market integrity. (SEC regulations)

In conclusion, if I had to choose, I would prefer ipci having broken SEC regulations but accomplished trials on the pending studies than the other way around.

but this goes back to the first question: why on hell keep your shareholders blind ?

This is Beyond my reach